PYXS insider trading
HealthcarePyxis Oncology, Inc.: insider trade history from SEC Form 4 filings.
About Pyxis Oncology, Inc.
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients with several cancer indications, which is in Phase 2 clinical trial for the treatment of tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and pancreatic ductal adenocarcinoma. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates, including micvotabart pelidotin and PYX-203, and other ADC product candidates directed to the licensed targets; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.
Company website: www.pyxisoncology.com
PYXS insider activity at a glance
FilingIQ tracks 71 insider transactions for PYXS in filings since Oct 12, 2021. The most recent transaction is dated Oct 1, 2026.
Across the full history, 16 open-market purchases
and 10 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on PYXS insider trades is 54.7/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest PYXS Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for PYXS?
- FilingIQ tracks 71 Form 4 insider transactions for PYXS (Pyxis Oncology, Inc.), covering filings from Oct 12, 2021 onwards. 1 of those are dated within the last 90 days.
- Are PYXS insiders net buyers or net sellers?
- Across the full Form 4 history for PYXS, 16 transactions (23%) were open-market purchases and 10 (14%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does PYXS insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is PYXS in?
- Pyxis Oncology, Inc. (PYXS) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $80.94M.
Methodology & sources
Every PYXS insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.